Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: In vitro plasma inactivation and pharmacological activity of its main metabolites

European Journal of Pharmaceutical Sciences

Volumn 39, Issue 5, 2010, Pages 283-290

  Sentellas, Sonia ^a   Ramos, Israel ^a   Albertí, Joan ^a   Salvà, Miquel ^a   Antón, Francisca ^a   Miralpeix, Montserrat ^a   Beleta, Jorge ^a   Gavaldà, Amadeu ^a  

^a Almirall Prodesfarma S A   (Spain)

Author keywords

Aclidinium bromide; Metabolites pharmacology; Plasma esterases; Plasma hydrolysis

Indexed keywords

3 HYDROXY 1 (3 PHENOXY PROPYL) 1 AZONIA BICYCLO[2.2.2]OCTANE BROMIDE; ACLIDINIUM BROMIDE; BRONCHODILATING AGENT; DITHIENYL GLYCOLIC ACID SODIUM SALT; DRUG METABOLITE; IPRATROPIUM BROMIDE; LAS 34823; LAS 34850; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC M5 RECEPTOR; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD SAMPLING; BRONCHODILATING ACTIVITY; BRONCHOSPASM; CONTROLLED STUDY; DRUG HYDROLYSIS; DRUG IDENTIFICATION; DRUG INACTIVATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; IN VITRO STUDY; IN VIVO STUDY; MALE; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; REVIEW; SPECIES DIFFERENCE;

ADMINISTRATION, INHALATION; ANIMALS; HUMANS; MUSCARINIC ANTAGONISTS; TROPANES;

EID: 77549086503     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.01.004     Document Type: Review

References (19)

1. Barnes P.J. The role of anticholinergics in chronic obstructive pulmonary disease. Am. J. Med. 117 Suppl. 12A (2004) 24S-32S
2. Ferrer P., Jansat J.M., and Garcia Gil E. Pharmacokinetics and safety of aclidinium bromide, a novel long-acting, inhaled anticholinergic, in healthy subjects. Am. J. Respir. Crit. Care Med. 177 (2008) A655
3. Gavaldà A., Miralpeix M., Ramos I., Otal R., Carreño C., Viñals M., Doménech T., Carcasona C., Reyes B., Vilella D., Gras J., Cortijo J., Morcillo E., Llenas J., Ryder H., and Beleta J. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J. Pharmacol. Exp. Ther. 331 (2009) 740-751
4. Gras J., Gavaldà A., and Llenas J. The preclinical safety profile of aclidinium bromide, a novel long-acting anticholinergic drug. Am. J. Respir. Crit. Care Med. 177 (2008) A654
5. Gras J., Llupià J., Llenas J., and Gavaldà A. The preclinical urinary and renal safety profile of aclidinium bromide, a novel long-acting anticholinergic drug. Eur. Resp. J. 32 Suppl. 52 (2008) P3640
6. Gross N.J., and Skorodin M.S. Role of the parasympathetic system in airway obstruction due to emphysema. N. Engl. J. Med. 311 (1984) 421-425
7. Gross N.J., and Skorodin M.S. Anticholinergic, antimuscarinic bronchodilators. Am. Rev. Respir. Dis. 129 (1984) 856-870
8. Gross N.J. Ipratropium bromide. N. Engl. J. Med. 319 (1988) 486-494
9. Gross N.J. Anticholinergic agents in asthma and COPD. Eur. J. Pharmacol. 533 (2006) 36-39
10. Hanania N.A., and Donohue J.F. Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. Proc. Am. Thorac. Soc. 4 (2007) 526-534
11. Jansat J.M., Lamarca R., Garcia Gil E., and Ferrer P. Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. Int. J. Clin. Pharmacol. Ther. 47 (2009) 460-468
12. Kesten S., Jara M., Wentworth C., and Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest 130 (2006) 1695-1703
13. Lee T.A., Pickard A.S., Au D.H., Bartle B., and Weiss K.B. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann. Intern. Med. 149 (2008) 380-390
14. Lieberman III J.A. Managing anticholinergic side effects. Prim. Care Companion J. Clin. Psychiatry 6 Suppl. 2 (2004) 20-23
15. Lopez A.D., Shibuya K., Rao C., Mathers C.D., Hansell A.L., Held L.S., Schmid V., and Buist S. Chronic obstructive pulmonary disease: current burden and future projections. Eur. Respir. J. 27 (2006) 397-412
16. Montero J.L., Antón F., Viñals M., Gras J., Gavaldà A., and Llenas J. Effect of aclidinium bromide, a novel long-acting anticholinergic, on salivation, colonic motility and faecal output in different animal models. Eur. Resp. J. 32 Suppl. 52 (2008) P3637
17. Prat M., Fernández D., Buil M.A., Crespo M., Casals G., Ferrer M., Tort L., Castro J., Monleón J.M., Gavaldà A., Miralpeix M., Ramos I., Doménech T., Vilella D., Antón F., Huerta J.M., Espinosa S., López M., Sentellas S., González M., Albertí J., Segarra V., Cárdenas A., Beleta J., and Ryder H. Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (aclidinium bromide). J. Med. Chem. 52 (2009) 5076-5092
18. Rabe K.F., Hurd S., Anzueto A., Barnes P.J., Buist S.A., Calverley P., Fukuchi Y., Jenkins C., Rodriguez-Roisin R., van Weel C., and Zielinski J. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 176 (2007) 532-555
19. Singh S., Loke Y.K., and Furberg C.D. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. A systematic review and meta-analysis. JAMA 300 (2008) 12